Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Severn Trent gives bullish outlook after delivering record FY profits

(Sharecast News) - Utility group Severn Trent reported record profits and said it expects to double earnings per share over the next three years, as it smashed market forecasts with its results for the 12 months ended 31 March. Profit before interest and tax rose 15.3% to £590.2m, with adjusted basic EPS jumping 41.2% to 112.1p - with both rates growth coming in at the highest levels in a decade. Analysts were expected adjusted EPS of 99p.

Revenues were up 3.8% during the period at £2.43bn, ahead of the £2.40bn consensus estimate.

The Midlands water provider said it delivered its "strongest-ever year operationally", investing £1.7bn through its capital programme, up 40% on last year and around treble the level of investment at the start of the AMP7 regulated asset management period, that ran between 2020 and 2025.

"In December our regulator approved £15bn of expenditure across the next five years, around twice the amount that was approved five years ago for the AMP7 period," said chief executive Liv Garfield.

"That will allow us to deliver further improvements for customers by 2030, including halving our usage of storm overflows, reducing the impact we have on river health, and delivering operational carbon net zero. And our performance this year gives confidence that we are primed to succeed."

Looking ahead, the firm predicts adjusted EPS will double over by the end of March 2028, helped by revenue growth outperformance, cost management and a strategic approach to financing.

The company raised its full-year dividend by 4.2% to 121.71p per share.

Shares were 1.7% higher at 2,758.57p by 0938 BST.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.